XML 188 R63.htm IDEA: XBRL DOCUMENT v3.24.4
Stockholders’ Deficiency (Details) - Schedule of Common Share Option Activity - USD ($)
 9 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2024
Dec. 31, 2023
Dec. 31, 2022
ACI Canada Legacy Performance Options [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Number of Options, Balance 380,842 397,642 265,642 272,842 380,842
Weighted Average Exercise Price, Balance $ 0.23   $ 0.22 $ 0.22 $ 0.23
Weighted Average Remaining Contractual Life (Years), Balance 5 years 10 months 28 days 6 years 8 months 4 days [1] 3 years 8 months 23 days 4 years 6 months 3 days 5 years 10 months 28 days
Aggregate Intrinsic Value, Balance $ 2,073,837   $ 3,338,055 $ 3,228,973 $ 2,073,837
Number of Options , Options exercisable     258,362 256,042  
Weighted Average Exercise Price, Options exercisable     $ 0.22    
Weighted Average Remaining Contractual Life (Years), Options exercisable,     3 years 8 months 15 days 4 years 5 months 19 days  
Aggregate Intrinsic Value, Options exercisable     $ 3,246,797    
Number of Options , Exercised     (7,200) (108,000) (14,000)
Weighted Average Exercise Price, Exercised     $ 0.22 $ 0.25  
Weighted Average Remaining Contractual Life (Years), Exercised    
Stock Option [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]          
Number of Options, Balance 220,243 211,903 815,974 826,887 220,243
Weighted Average Exercise Price, Balance $ 6.86   $ 4.28 $ 4.44 $ 6.86
Weighted Average Remaining Contractual Life (Years), Balance 8 years 5 months 19 days 9 years 2 months 19 days 8 years 6 months 29 days 9 years 25 days 8 years 5 months 19 days
Aggregate Intrinsic Value, Balance [2]   $ 6,939,454 $ 6,647,828
Number of Options , Options exercisable     527,881 322,026  
Weighted Average Exercise Price, Options exercisable     $ 4.41    
Weighted Average Remaining Contractual Life (Years), Options exercisable,     8 years 4 months 6 days 9 years 25 days  
Aggregate Intrinsic Value, Options exercisable [2]     $ 4,418,911    
Number of Options, Granted       647,600 46,800
Weighted Average Exercise Price, Granted       $ 4.16  
Weighted Average Remaining Contractual Life (Years), Granted      
Number of Options, Expired       (30,911) (35,800)
Weighted Average Exercise Price, Expired       $ 25.34  
Weighted Average Remaining Contractual Life (Years), Expired      
Number of Options , Exercised     (10,913) [3] (10,045) [4] (2,660)
Weighted Average Exercise Price, Exercised     $ 4.79 [3] $ 4.16 [5]  
Weighted Average Remaining Contractual Life (Years), Exercised     [3] [5]
[1] The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company’s common share on December 31, 2023, and 2022. The calculation excludes options with an exercise price higher than the closing price of the Company’s share on December 31, 2023 and 2022.
[2] The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company’s common share. The calculation excludes options with an exercise price higher than the closing price of the Company’s share on the reporting date.
[3] In accordance with the Company’s 2023 Option Plan, option holders exercised 10,913 Common Share options on a cashless basis (net exercise) for the issuance of 7,700 Common Shares.
[4] In accordance with the Company’s 2023 Option Plan, option holders exercised 10,045 Common Share options on a cashless basis (net exercise) for the issuance of 6,600 Common Shares.
[5] In accordance with the Company’s 2023 Option Plan, option holders exercised 10,045 Common Share options on a cashless basis (net exercise) for the issuance of 6,600 Common Shares.